Skip to content

Alumis Inc. ALMS EBITDA margin

EBITDA margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
27.2%-2.2pp
Amgen logo
AmgenAMGN
41.5%+3.4pp
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
23.1%+13.1pp
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-35,299.7%-38,670pp
Immunome logo
ImmunomeIMNM
-5,886.7%-11,897pp
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-240.6%+497pp

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

Based on trailing twelve months.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s EBITDA margin?
Alumis Inc. (ALMS) reported EBITDA margin of -5,322.1% in Q1 2026.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.